Análisis comparativo de las infecciones respiratorias agudas de etiología viral en menores de 6 meses con y sin nirsevimab en Baleares (2022-2023 y 2023-2024)

IF 2.6 4区医学 Q3 INFECTIOUS DISEASES

Enfermedades infecciosas y microbiologia clinica Pub Date : 2025-04-01 DOI:10.1016/j.eimc.2024.07.007

Jordi Reina , Ane Iturbe , Julia Viana-Ramírez , Guida Sbert , Jaume Carrasco , Joaquín Dueñas

{"title":"Análisis comparativo de las infecciones respiratorias agudas de etiología viral en menores de 6 meses con y sin nirsevimab en Baleares (2022-2023 y 2023-2024)","authors":"Jordi Reina , Ane Iturbe , Julia Viana-Ramírez , Guida Sbert , Jaume Carrasco , Joaquín Dueñas","doi":"10.1016/j.eimc.2024.07.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Since 2023, a monoclonal antibody (nirsevimab) specifically directed against the preF form of RSV has been marketed in Spain. The impact of late immunization in the population <6months as a cause of other respiratory infections requiring a hospital visit has been analyzed.</div></div><div><h3>Material and methods</h3><div>The viral etiology of acute respiratory infections (ARIs) diagnosed in the 2022-2023 and 2023-2024 seasons has been prospectively compared, and in this last season between recipients and non-recipients of nirsevimab. Global provisional coverage was 77% of the population.</div></div><div><h3>Results</h3><div>In the 2022-2023 season, 303 <6months with an ARI were detected, while in the 2023-2024 season there were 278 minors (19% less). The positivity in the first season was 79.9% compared to 70.5% in the current season. A significant difference has been observed in the detection of RSV between both groups and a decrease of 82.9% of cases in the current season. Of the 278 cases <6months detected in the 2023-2024 season, 192 (69.1%) received immunization with nirsevimab and 86 (30.9%) did not receive it. The percentage of positivity in those immunized was 69.3%, compared to 73.3% in those not immunized. Significant differences have been observed in the detections of RSV and influenza between both groups.</div></div><div><h3>Conclusions</h3><div>Immunization at <6months with nirsevimab has shown a significant reduction in RSV infections compared to the previous season. It does not seem, however, that it can reduce infections by other respiratory viruses.</div></div>","PeriodicalId":11608,"journal":{"name":"Enfermedades infecciosas y microbiologia clinica","volume":"43 4","pages":"Pages 193-196"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Enfermedades infecciosas y microbiologia clinica","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0213005X24002854","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Since 2023, a monoclonal antibody (nirsevimab) specifically directed against the preF form of RSV has been marketed in Spain. The impact of late immunization in the population < 6 months as a cause of other respiratory infections requiring a hospital visit has been analyzed.

Material and methods

The viral etiology of acute respiratory infections (ARIs) diagnosed in the 2022-2023 and 2023-2024 seasons has been prospectively compared, and in this last season between recipients and non-recipients of nirsevimab. Global provisional coverage was 77% of the population.

Results

In the 2022-2023 season, 303 < 6 months with an ARI were detected, while in the 2023-2024 season there were 278 minors (19% less). The positivity in the first season was 79.9% compared to 70.5% in the current season. A significant difference has been observed in the detection of RSV between both groups and a decrease of 82.9% of cases in the current season. Of the 278 cases < 6 months detected in the 2023-2024 season, 192 (69.1%) received immunization with nirsevimab and 86 (30.9%) did not receive it. The percentage of positivity in those immunized was 69.3%, compared to 73.3% in those not immunized. Significant differences have been observed in the detections of RSV and influenza between both groups.

Conclusions

Immunization at < 6 months with nirsevimab has shown a significant reduction in RSV infections compared to the previous season. It does not seem, however, that it can reduce infections by other respiratory viruses.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Enfermedades infecciosas y microbiologia clinica 医学-传染病学

CiteScore

2.10

自引率

8.00%

发文量

194

审稿时长

29 days

期刊介绍： Hoy está universalmente reconocida la renovada y creciente importancia de la patología infecciosa: aparición de nuevos agentes patógenos, de cepas resistentes, de procesos con expresión clínica hasta ahora desconocida, de cuadros de una gran complejidad. Paralelamente, la Microbiología y la Infectología Clínicas han experimentado un gran desarrollo como respuesta al reto planteado por la actual patología infecciosa. Enfermedades Infecciosas y Microbiología Clínica es la Publicación Oficial de la Sociedad Española SEIMC. Cumple con la garantía científica de esta Sociedad, la doble función de difundir trabajos de investigación, tanto clínicos como microbiológicos, referidos a la patología infecciosa, y contribuye a la formación continuada de los interesados en aquella patología mediante artículos orientados a ese fin y elaborados por autores de la mayor calificación invitados por la revista.